- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-668/17 P: Judgment of the Court (Fourth Chamber) of 3 July 2019 — Viridis Pharmaceutical Ltd. v European Union Intellectual Property Office (EUIPO), Hecht-Pharma GmbH (Appeal — European Union trade mark — Revocation proceedings — Word mark Boswelan — No genuine use — Use of the mark in a clinical trial prior to filing an application for authorisation to place a medicinal product on the market — Proper reason for non-use — Concept)
ECLI:EU:UNKNOWN:62017CA0668
62017CA0668
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 305/8
(Case C-668/17 P) (<span class="super note-tag">1</span>)
(Appeal - European Union trade mark - Revocation proceedings - Word mark Boswelan - No genuine use - Use of the mark in a clinical trial prior to filing an application for authorisation to place a medicinal product on the market - Proper reason for non-use - Concept)
(2019/C 305/09)
Language of the case: German
Parties
Appellant: Viridis Pharmaceutical Ltd. (represented by C. Spintig, S. Pietzcker and M. Prasse, Rechtsanwälte)
Other parties to the proceedings: European Union Intellectual Property Office (EUIPO) (represented by S. Hanne, acting as Agent), Hecht-Pharma GmbH (represented by J. Sachs and C. Sachs, Rechtsanwälte)
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Viridis Pharmaceutical Ltd to pay, in addition to its own costs, those incurred by the European Union Intellectual Property Office (EUIPO) and Hecht-Pharma GmbH.
(<span class="note"> <a id="ntr1-C_2019305EN.01000801-E0001" href="#ntc1-C_2019305EN.01000801-E0001">*1</a> </span>) OJ C 83, 5.3.2018.